Cancer Genetics, Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011
Total Revenue 6,610 4,302 3,019
Cost of Revenue 4,925 3,929 3,117
Gross Profit 1,685 373 (98)
Operating Expenses
Research and Development 2,190 2,112 2,074
Sales, General and Admin. 7,957 5,901 6,013
Non-Recurring Items - - -
Other - - -
Operating Income (8,462) (7,641) (8,185)
Income From Continuing Operations
Add'l Income/Expense Items (2,187) 5,676 (10,388)
Earnings Before Interest and Tax (10,649) (1,965) (18,573)
Interest Expense 2,388 4,701 1,314
Earnings Before Tax (13,036) (6,666) (19,887)
Income Tax (664) - -
Minority Interest - - -
Equity Earnings Unconsolidated Subsidiary - - -
Net Income Cont. Operations (12,373) (6,666) (19,887)
Non Recurring Events
Discontinued Operations - - -
Extraordinary Items - - -
Effect of Accounting Changes - - -
Other Items - - -
Net Income (12,373) (6,666) (19,887)
Preferred Stock and Other Adjustments - - -
Net Income Applicable to Common Shareholders (12,373) (6,666) (19,887)